Recombinant salmonella-based 4-1BBL vaccine enhances T cell immunity and inhibits the development of colorectal cancer in rats: In vivo effects of vaccine containing 4-1BBL

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Ye, Jianxin ^a   Li, Ling ^a   Zhang, Yuanting ^a   Zhang, Xueguang ^b   Ren, Daming ^c   Chen, Weichang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

4 1BBL; Colorectal cancer; Recombinant attenuated salmonella; T cell based cellular immunity

Indexed keywords

CANCER VACCINE; CD137 LIGAND; GAMMA INTERFERON; PHOSPHATE BUFFERED SALINE; RECOMBINANT SALMONELLA BASED 4 1BB LIGAND VACCINE; SALMONELLOSIS VACCINE; UNCLASSIFIED DRUG; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BLOOD; CANCER IMMUNOTHERAPY; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLON; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; IN VIVO STUDY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECTUM; SPLEEN; T LYMPHOCYTE; ANIMAL; COLORECTAL TUMOR; DRUG EFFECT; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY;

RATTUS; SALMONELLA;

4-1BB LIGAND; ANIMALS; CANCER VACCINES; COLORECTAL NEOPLASMS; HUMANS; LYMPHOCYTE ACTIVATION; MALE; NEOPLASMS, EXPERIMENTAL; RATS; SALMONELLA VACCINES; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 84873720137     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-8     Document Type: Article

References (26)

1. Cancer immunotherapy: moving beyond current vaccines. Rosenberg SA, Yang JC, Restifo NP, Nat Med 2004 10 909 915 10.1038/nm1100 15340416 (Pubitemid 39273730)
2. Immunotherapy of cancer with 4-1BB. Vinay DS, Kwon BS, Mol Cancer Ther 2012 11 1062 1070 10.1158/1535-7163.MCT-11-0677 22532596
3. Costimulatory molecules as adjuvants for immunotherapy. Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C, Grosenbach DW, Gulley JL, Arlen PM, Marshall JL, Panicali D, Schlom J, Front Biosci 2006 11 788 803 10.2741/1837 16146771 (Pubitemid 43258182)
4. Role of 4-1BB: 4-1BB ligand in cancer immunotherapy. Cheuk AT, Mufti GJ, Guinn BA, Cancer Gene Ther 2004 11 215 226 10.1038/sj.cgt.7700670 14671675 (Pubitemid 38280524)
5. 4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Laderach D, Movassagh M, Johnson A, Mittler RS, Galy A, Int Immunol 2002 14 1155 1167 10.1093/intimm/dxf080 12356681 (Pubitemid 35175223)
6. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, Brown TJ, Emswiler J, Raecho H, Larsen CP, J Exp Med 1997 186 47 55 10.1084/jem.186.1.47 9206996 (Pubitemid 27304846)
7. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K, Watts TH, J Immunol 2001 167 1313 1324 11466348 (Pubitemid 32703127)
8. 4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity. Cooper D, Bansal-Pakala P, Croft M, Eur J Immunol 2002 32 521 529 10.1002/1521- 4141(200202)32:2<521::AID-IMMU521>3.0.CO;2-X 11828369 (Pubitemid 34173343)
9. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, Kwon BS, J Immunol 2002 169 4882 4888 12391199 (Pubitemid 35217152)
10. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, Bandura-Morgan L, Shirwan H, Cancer Res 2009 69 4319 4326 10.1158/0008-5472.CAN- 08-3141 19435920
11. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ, Yolcu ES, Shirwan H, Cancer Res 2010 70 3945 3954 10.1158/0008-5472.CAN-09-4480 20406989
12. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Zhang N, Sadun RE, Arias RS, Flanagan ML, Sachsman SM, Nien YC, Khawli LA, Hu P, Epstein AL, Clin Cancer Res 2007 13 2758 2767 10.1158/1078-0432.CCR-06-2343 17460060 (Pubitemid 46788045)
13. Recombinant attenuated Salmonella harboring 4-1BB ligand gene enhances cellular immunity. Ye JX, Zhang YT, Zhang XG, Ren DM, Chen WC, Vaccine 2009 27 1717 1723 10.1016/j.vaccine.2009.01.031 19187795
14. The President's cancer, the Dukes classification, and confusion. Kyriakos M, Arch Pathol Lab Med 1985 109 1063 1066 3907586
15. TNF/TNFR family members in costimulation of T cell responses. Watts TH, Annu Rev Immunol 2005 23 23 68 10.1146/annurev.immunol.23.021704.115839 15771565 (Pubitemid 40563164)
16. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Croft M, Nat Rev Immunol 2003 3 609 620 10.1038/nri1148 12974476 (Pubitemid 37328664)
17. 4-1BB-like molecule is expressed in islet-infiltrating mononuclear cells and in the gray matter of the brain. Lim HY, Kim KK, Zhou FC, Yoon JW, Hill JM, Kwon BS, Cell Biol Int 2002 26 271 278 10.1006/cbir.2001.0847 11991655
18. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, Spencer T, Dillehay D, Kwon B, Chen L, J Immunol 2007 178 4194 4213 17371976 (Pubitemid 46492370)
19. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. Lin GH, Sedgmen BJ, Moraes TJ, Snell LM, Topham DJ, Watts TH, J Immunol 2009 182 934 947 19124736
20. Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity. Ganguly S, Liu J, Pillai VB, Mittler RS, Amara RR, Vaccine 2010 28 1300 1309 10.1016/j.vaccine.2009.11.020 19944789
21. Histogenesis and growth pattern of 1,2-dimethylhydrazine-induced rat colon adenocarcinoma. Maskens AP, Cancer Res 1976 36 1585 1592 178424
22. Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. Rosenberg SA, Spiess PJ, Kleiner DE, J Immunother 2002 25 218 225 10.1097/00002371-200205000-00004 12000863 (Pubitemid 34533311)
23. Lymphocytes subsets in normal individuals: analysis by four color immunofluorescence and flow cytometry on whole blood. Schiavon V, Roth P, Bolton WE, Farcet JP, Bensussan A, Boumsell L, Tissue Antigens 1996 48 312 318 10.1111/j.1399-0039.1996.tb02650.x 8946685 (Pubitemid 26377571)
24. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA, Proc Natl Acad Sci USA 2006 103 2788 2793 10.1073/pnas.0511161103 16477002
25. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. Tomala J, Chmelova H, Mrkvan T, Rihova B, Kovar M, J Immunol 2009 183 4904 4912 10.4049/jimmunol.0900284 19801515
26. Treatment with AM3 restores defective T-cell function in COPD patients. Reyes E, Prieto A, de la Hera A, de Lucas P, Alvarez-Sala R, Alvarez-Sala JL, Alvarez-Mon M, Chest 2006 129 527 535 10.1378/chest.129.3.527 16537848